Fluoroquinolones To Get “Better” But Not Necessarily Stronger Warning On Nerve Damage
This article was originally published in The Pink Sheet Daily
Risk of peripheral neuropathy is already in labeling and FDA doesn’t want to require a black box, illustrating the agency’s ongoing challenge to fully communicate risks without unduly limiting access or use.
You may also be interested in...
Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.
Advisory committee unsure how to describe fluoroquinolone-associated disability in labeling.
Joint advisory committee meeting will discuss post-marketing safety data, including adverse events across organ systems.